T
Torsten Wuestefeld
Researcher at University of Tübingen
Publications - 31
Citations - 4299
Torsten Wuestefeld is an academic researcher from University of Tübingen. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 13, co-authored 21 publications receiving 3318 citations. Previous affiliations of Torsten Wuestefeld include Hochschule Hannover & Hannover Medical School.
Papers
More filters
Journal ArticleDOI
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Juan Carlos Acosta,Ana Banito,Torsten Wuestefeld,Athena Georgilis,Peggy Janich,Jennifer P. Morton,Dimitris Athineos,Tae-Won Kang,Felix Lasitschka,Mindaugas Andrulis,Gloria Pascual,Kelly J. Morris,Sadaf Khan,Hong Jin,Gopuraja Dharmalingam,Ambrosius P. Snijders,Thomas L. Carroll,David Capper,Catrin Pritchard,Gareth J. Inman,Thomas Longerich,Owen J. Sansom,Salvador Aznar Benitah,Lars Zender,Jesús Gil +24 more
TL;DR: It is demonstrated that the SASP can cause paracrine senescence and impact on tumour suppression andSenescence in vivo and TGF-β ligands play a major role by regulating p15INK4b and p21CIP1.
Journal ArticleDOI
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Tae-Won Kang,Tetyana Yevsa,Norman Woller,Lisa Hoenicke,Torsten Wuestefeld,Daniel Dauch,Anja Hohmeyer,Marcus Gereke,Ramona Rudalska,Anna Potapova,Marcus Iken,Mihael Vucur,Siegfried Weiss,Mathias Heikenwalder,Mathias Heikenwalder,Sadaf Khan,Jesús Gil,Dunja Bruder,Michael P. Manns,Peter Schirmacher,Frank Tacke,Michael Ott,Tom Luedde,Thomas Longerich,Stefan Kubicka,Lars Zender +25 more
TL;DR: It is shown that oncogene-induced senescence occurs in otherwise normal murine hepatocytes in vivo, and how the cellularsenescence program is involved in tumour immune surveillance by mounting specific immune responses against antigens expressed in pre-malignant senescent cells is illustrated.
Journal ArticleDOI
mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
Nicolás Herranz,Suchira Gallage,Massimiliano Mellone,Torsten Wuestefeld,Sabrina Klotz,Christopher J. Hanley,Selina Raguz,Juan Carlos Acosta,Andrew J. Innes,Ana Banito,Athena Georgilis,Alex Montoya,Katharina Wolter,Gopuraja Dharmalingam,Peter Faull,Thomas L. Carroll,Juan Pedro Martinez-Barbera,Pedro R. Cutillas,Pedro R. Cutillas,Florian Reisinger,Mathias Heikenwalder,Mathias Heikenwalder,Richard A. Miller,Dominic J. Withers,Lars Zender,Gareth J. Thomas,Jesús Gil +26 more
TL;DR: A mechanism by which mTOR controls the SASP is reported by differentially regulating the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1.
Journal ArticleDOI
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Ramona Rudalska,Daniel Dauch,Thomas Longerich,Katherine McJunkin,Torsten Wuestefeld,Tae-Won Kang,Anja Hohmeyer,Marina Pesic,Josef Leibold,Anne von Thun,Peter Schirmacher,Johannes Zuber,Karl-Heinz Weiss,Scott Powers,Nisar P. Malek,Martin Eilers,Bence Sipos,Scott W. Lowe,Robert Geffers,Stefan Laufer,Lars Zender +20 more
TL;DR: A system that enables pooled shRNA screening directly in mouse hepatocellular carcinomas in vivo to identify genes likely to be involved in therapy resistance is described, suggesting that a combination of sorafenib and Mapk14 blockade is a promising approach to overcoming therapy resistance of human HCC.
Journal ArticleDOI
A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
Daniel Dauch,Ramona Rudalska,Giacomo Cossa,Jean-Charles Nault,Tae-Won Kang,Tae-Won Kang,Torsten Wuestefeld,Anja Hohmeyer,Sandrine Imbeaud,Tetyana Yevsa,Lisa Hoenicke,Tatu Pantsar,Przemyslaw Bozko,Nisar P. Malek,Thomas Longerich,Stefan Laufer,Antti Poso,Antti Poso,Jessica Zucman-Rossi,Martin Eilers,Lars Zender,Lars Zender +21 more
TL;DR: Conformation-changing AURKA inhibitors, with one of them currently being tested in early clinical trials, suppressed tumor growth and prolonged survival in mice bearing Trp53-deficient, NRAS-driven MYC-expressing hepatocellular carcinomas (HCCs), thus suggesting a therapeutic strategy for this subgroup of human HCCs.